Nail Fungus Answers

Nail Fungus Condition and Treatment Data (Overview)

Compiled survey data used to help develop our rating criteria on this website.

How long have you suffered from nail fungus?

Do you suffer from finger or toenail fungus or both?

Have you recovered from nail fungus?

What treatments have you tried?

How were you diagnosed with nail fungus?

Scientific Case Studies


1986 -

Enhancement of the topical tolnaftate delivery for the treatment of tinea pedis via provesicular gel systems."

2007 -

"Topical treatments for fungal infections of the skin and nails of the foot."

1992 -

"The tea tree oil group (24/37) and the tolnaftate group (19/33) showed significant improvement in clinical condition when compared to the placebo group (14/34; p = 0.022 and p = 0.018 respectively)."

1980 -

"In one hundred and three patients studied, both the clinical and mycological effects of the two antifungal agents were indistinguishable. Both were significantly more effective than the placebo."


2004 -

"Itraconazole, a triazole antifungal agent, has been widely used for onychomycosis with high cure rates. Unchanged itraconazole and a major metabolite hydroxy-itraconazole reach the nail with a strong affinity for keratin. The aim of this study was to elucidate clinical effectiveness and pharmacokinetic profiles of a 6-month continuous itraconazole treatment at a daily dose of 100 mg. Nail growth, the decrease in nail turbidity, and the nail concentrations of unchanged- and hydroxy-itraconazole were investigated. The affected nails we examined demonstrated nail growth proportional to the decrease in turbidity and a quick increase in drug concentration with a long duration of a high concentration after cessation. Our results support the hypothesis that this continuous therapy is a good modality for onychomycosis."

2014 -

"Two new topical antifungals, efinaconazole 10% solution and tavaborole 5% solution, both appear to offer advantages over ciclopirox 8% nail lacquer, although it is not possible to directly compare the three topical products definitively."

2015 -

"In a study (5) with 53 patients with toenail onychomycosis caused by dermatophytes, 27 patients were treated with itraconazole 200 mg/daily, while other 26 of them were treated with terbinafine 250 mg/daily for 3 months. The achieved clinical and mycologic cure rate for group treated with itraconazole was 60.9% and 64.7% for terbinafine group, while remained other patients had improvement. In another study (6), 60 patients divided into 3 groups, were treated with 250mg/d terbinafine, 500 mg/d terbinafine for a week per month, and 400mg/d itraconazole for a week per month, respectively. In the all 3 groups the response to the treatment was similar, about 80% cure rate, and without significant difference. Honeyman et al. (7) have treated 85 patients with itraconazole 200mg/d, and other 82 patients with terbinafine 250mg/d for 4 months. At the end of the month 12, clinical cure rate for terbinafine group was 57.8%, and 62.6% for itraconazole group. The mycologic cure rate for terbinafine was 95.3% and 84.3% for itraconazole."


2002 -

"A study of dermatophytes and their in-vitro antifungal sensitivity."

1997 -

"In-vitro permeability of the human nail and of a keratin membrane from bovine hooves: prediction of the penetration rate of antimycotics through the nail plate and their efficacy."

Undecylenic Acid:

2016 -

“Luliconazole and lanoconazole revealed potent activity against all dermatophyte isolates. Anidulafungin, caspofungin, and luliconazole showed the best activity with the lowest geometric mean 0.01, 0.016, and 0.018 μg/ml, respectively, followed by tolnaftate (0.06 μg/ml), terbinafine (0.07 μg/ml), itraconazole (0.183 μg/ml), butenafine (0.188 μg/ml), econazole (0.20 μg/ml), lanoconazole (0.24 μg/ml), griseofulvin (1.28 μg/ml), miconazole (2.34 μg/ml) and fluconazole (15.34 μg/ml). The current study demonstrated luliconazole and lanoconazole displayed excellent activity against all dermatophyte isolates, although the majority of dermatophyte isolates showed low susceptibility to griseofulvin and very low to miconazole, and fluconazole.”

1980 -

"In one hundred and three patients studied, both the clinical and mycological effects of the two antifungal agents were indistinguishable. Both were significantly more effective than the placebo."